Acute Myeloid Leukemia With CEBPA Mutations: Current Progress and Future Directions.
Su L, Shi YY, Liu ZY, Gao SJ.
Front Oncol. 2022 Feb 1;12:806137. doi: 10.3389/fonc.2022.806137. eCollection 2022.
CEBPA-bZip mutations are associated with favorable prognosis in de novo AML: a report from the Children's Oncology Group.
Tarlock K, Lamble AJ, Wang YC, Gerbing RB, Ries RE, Loken MR, Brodersen LE, Pardo L, Leonti A, Smith JL, Hylkema TA, Woods WG, Cooper TM, Kolb EA, Gamis AS, Aplenc R, Alonzo TA, Meshinchi S.
Blood. 2021 Sep 30;138(13):1137-1147. doi: 10.1182/blood.2020009652.
A concise review on the molecular genetics of acute myeloid leukemia.
Padmakumar D, Chandraprabha VR, Gopinath P, Vimala Devi ART, Anitha GRJ, Sreelatha MM, Padmakumar A, Sreedharan H.
Leuk Res. 2021 Dec;111:106727. doi: 10.1016/j.leukres.2021.106727. Epub 2021 Oct 16.
CEBPA mutations in 4708 patients with acute myeloid leukemia: differential impact of bZIP and TAD mutations on outcome.
Taube F, Georgi JA, Kramer M, Stasik S, Middeke JM, Röllig C, Krug U, Krämer A, Scholl S, Hochhaus A, Brümmendorf TH, Naumann R, Petzold A, Mulet-Lazaro R, Valk PJM, Steffen B, Einsele H, Schaich M, Burchert A, Neubauer A, Schäfer-Eckart K, Schliemann C, Krause SW, Hänel M, Noppeney R, Kaiser U, Baldus CD, Kaufmann M, Herold S, Stölzel F, Sockel K, von Bonin M, Müller-Tidow C, Platzbecker U, Berdel WE, Serve H, Ehninger G, Bornhäuser M, Schetelig J, Thiede C; Study Alliance Leukemia (SAL).
Blood. 2022 Jan 6;139(1):87-103. doi: 10.1182/blood.2020009680.
Familial CEBPA-mutated acute myeloid leukemia.
Tawana K, Rio-Machin A, Preudhomme C, Fitzgibbon J.
Semin Hematol. 2017 Apr;54(2):87-93. doi: 10.1053/j.seminhematol.2017.04.001. Epub 2017 Apr 7.
Prognostic impact of CEBPA mutational subgroups in adult AML.
Georgi JA, Stasik S, Kramer M, Meggendorfer M, Röllig C, Haferlach T, Valk P, Linch D, Herold T, Duployez N, Taube F, Middeke JM, Platzbecker U, Serve H, Baldus CD, Muller-Tidow C, Haferlach C, Koch S, Berdel WE, Woermann BJ, Krug U, Braess J, Hiddemann W, Spiekermann K, Boertjes EL, Hills RK, Burnett A, Ehninger G, Metzeler K, Rothenberg-Thurley M, Dufour A, Dombret H, Pautas C, Preudhomme C, Fenwarth L, Bornhäuser M, Gale R, Thiede C.
Leukemia. 2024 Feb;38(2):281-290. doi: 10.1038/s41375-024-02140-x. Epub 2024 Jan 16.
AML classification in the year 2023: How to avoid a Babylonian confusion of languages.
Huber S, Baer C, Hutter S, Dicker F, Meggendorfer M, Pohlkamp C, Kern W, Haferlach T, Haferlach C, Hoermann G.
Leukemia. 2023 Jul;37(7):1413-1420. doi: 10.1038/s41375-023-01909-w. Epub 2023 Apr 29.
The genetic landscape of germline DDX41 variants predisposing to myeloid neoplasms.
Li P, Brown S, Williams M, White T, Xie W, Cui W, Peker D, Lei L, Kunder CA, Wang HY, Murray SS, Vagher J, Kovacsovics T, Patel JL.
Blood. 2022 Aug 18;140(7):716-755. doi: 10.1182/blood.2021015135.
AML with CEBPA mutations: A comparison of ICC and WHO-HAEM5 criteria in patients with 20% or more blasts.
Zhao D, Zhou Q, Zarif M, Eladl E, Wei C, Atenafu EG, Schuh A, Tierens A, Yeung YWT, Minden MD, Chang H.
Leuk Res. 2023 Nov;134:107376. doi: 10.1016/j.leukres.2023.107376. Epub 2023 Aug 29.
CEBPA mutations in AML: site matters.
Bullinger L.
Blood. 2022 Jan 6;139(1):6-7. doi: 10.1182/blood.2021013557.
